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Abstract
Background: The hCMV promoter is very commonly used for high level expression of transgenes
in mammalian cells, but its utility is hindered by transcriptional silencing. Large genomic fragments
incorporating the CpG island region of the HNRPA2B1  locus are resistant to transcriptional
silencing.
Results : In this report we describe studies on the use of a novel series of vectors combining the
HNRPA2B1 CpG island with the hCMV promoter for expression of transgenes in CHO-K1 cells.
We show that the CpG island gives at least twenty-fold increases in the levels of EGFP and EPO
observed in pools of transfectants, and that transgene expression levels remain high in such pools
for more than 100 generations. These novel vectors also allow facile isolation of clonal CHO-K1
cell lines showing stable, high-level transgene expression.
Conclusion: Vectors incorporating the hnRPA2B1 CpG island give major benefits in transgene
expression from the hCMV promoter, including substantial improvements in the level and stability
of expression. The utility of these vectors for the improved production of recombinant proteins in
CHO cells has been demonstrated.
Background
Despite recent progress in elucidating the molecular basis
of gene expression the practicality of achieving reliable,
stable, high-level transgene expression in mammalian
cells remains a major challenge. This inefficiency of trans-
gene expression is largely attributable to transcriptional
silencing, which typically involves methylation at CpG
DNA sequences, histone deacetylation and chromatin
condensation in the vicinity of the integration site [1,2].
When exogenous genes are introduced into cultured cells,
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many of the integration events lead to rapid transgene
silencing, whilst the remainder give widely varying expres-
sion levels [3,4]. For this reason the use of cultured mam-
malian cells to produce recombinant proteins (except at
very small scale) usually requires labour-intensive isola-
tion of rare, clonal cell lines that stably express the trans-
gene at high levels. Similarly, chromatin structure-related
silencing and extreme variability in expression hinder the
use of transgenic animals for purposes such as defining
novel gene function and manufacture of therapeutic pro-
teins [5,6]. Furthermore, achieving clinical utility with
gene therapies (especially for chronic diseases), is greatly
hindered by inadequate levels and duration of therapeutic
transgene expression, resulting partly from transcriptional
silencing [7,8]. The identification of elements capable of
maintaining a transcriptionally competent ("open") chro-
matin domain resistant to silencing, irrespective of tissue
type or integration site, is therefore an important objective
in the development of technology giving more efficient
transgene expression in mammalian cells, for many
important applications.
We have reported previously that large DNA fragments
containing CpG islands from the human TBP-PSMB1 and
HNRPA2B1-CBX3 loci (designated TBP and RNP below)
are resistant to heterochromatin-mediated silencing of
these genes [9]. These regions are structurally similar, con-
taining dual divergently transcribed promoters embedded
within an extended methylation-free CpG island. The
divergent promoters drive expression of ubiquitously
expressed housekeeping genes, encoding the TATA bind-
ing protein and proteasome component-B1 in the case of
the TBP locus, and the heterogeneous ribonucleoprotein A2/
B1 and chromobox homolog 3 in the case of the RNP locus.
Our previous studies showed that with these large CpG
island-containing fragments, active transcription from the
endogenous promoters was maintained even upon inte-
gration into centromeric heterochromatin, that single
copy integration at different sites gave very similar levels
of gene expression, and that position effect variegation
was greatly reduced [9].
The endogenous promoters of the housekeeping genes at
the TBP and RNP loci are relatively weak. In this paper we
report studies with a series of novel expression vectors in
which the CpG island from the RNP locus was combined
with the immediate early promoter/enhancer of the
human cytomegalovirus (hCMV), the promoter most
commonly used to achieve strong, non-selective expres-
sion in mammalian cells for many applications. We show
that the RNP CpG island confers major benefits in trans-
gene expression from this promoter, including substantial
improvements in the level of expression and proportion
of transfected cells that express at detectable levels. We
show that with these novel vectors expression remains
high on prolonged subculturing. We also demonstrate the
utility of these vectors for the improved production of
recombinant proteins in Chinese Hamster Ovary (CHO)
cells.
Results and Discussion
RNP CpG island fragments enhance transgene expression 
and confer resistance to silencing when linked to the 
hCMV promoter
Our previous report concerned the ability of large DNA
fragments containing the RNP CpG island to inhibit tran-
scriptional silencing of genes expressed from the promot-
ers of the endogenous housekeeping genes [9]. With a
view to developing vectors allowing facile generation of
constructs for improved, high-level transgene expression,
we first evaluated smaller fragments containing this CpG
island. As shown in Figure 1A the HNRPA2B1 and CBX3
genes are divergently transcribed from two separate pro-
moters embedded within a methylation-free CpG island
approximately 3 kb in length [9]. We evaluated three CpG
island-containing fragments of length 8.0 kb, 4.0 kb and
1.5 kb (Figure 1B). All three fragments contained the dual
divergent promoters. The 8.0 kb and 4.0 kb fragments
both contained the entire methylation-free CpG island,
while the 1.5 kb fragment contained approximately half
of this region. These fragments were incorporated into
vectors for expression of EGFP from the hCMV promoter
as indicated in Figure 1B.
Following stable transfection of these constructs into
CHO-K1 cells, EGFP expression was quantified by FACS-
can analysis of transfectant pools after 33 and 200 gener-
ations of culture (Figure 2). After 33 generations pools
derived with hCMV-EGFP showed a characteristically wide
range of expression levels, manifest as a broad plateau
rather than a discreet peak of EGFP expressing cells. Inter-
estingly, 48% of the cells showed no detectable expression
and only 6% of the cells showed expression exceeding
1000 fluorescence units at this stage of culture. By con-
trast, after 33 generations of culture for the 8.0 and 4.0 kb
RNP-EGFP containing populations only 3% and 5% of
the cells respectively showed no detectable expression,
with 88% and 84% of the cells respectively showing
median expression exceeding 1000 fluorescence units.
The majority of cells in these populations showed very
high expression levels, as evidenced by the steep shoulder
at the end of the detectable range. Similarly, after 200 gen-
erations of culture these stably transfected cell popula-
tions contained 75% and 73% of cells with median
fluorescence exceeding 1000 units. At the same stage of
culture only 2% of cells in the pool transfected with
hCMV-EGFP showed fluorescence exceeding 1000 units.
Figure 3 (A and B) shows the results (in histogram format)
of similar experiments, conducted over 199 or 107BMC Biotechnology 2005, 5:17 http://www.biomedcentral.com/1472-6750/5/17
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generations of culture, with vectors containing the 8.0, 4.0
and 1.5 kb CpG islands. The 1.5 kb RNP CpG island frag-
ment conferred improvements in level of expression from
the  hCMV  promoter and percentage of cells showing
detectable EGFP expression that were very similar to those
observed for the larger fragments. FACScan analysis also
showed the characteristic steep shoulder associated with
the larger RNP fragments (data not shown). Overall, the
8.0, 4.0 and 1.5 kb RNP fragments reproducibly gave 20-
to 40-fold increases in the median expression levels of
EGFP compared to that observed for the hCMV promoter
alone, and these increased levels were maintained
through at least 107 generations of continuous culture.
The effects of the CpG island fragments on EGFP expres-
sion level and stability were further studied using clonal
CHO-K1 cell lines rather than transfected pools. Figure 4A
shows the results of quantifying EGFP expression for
clones isolated following stable transfection with the
hCMV-EGFP and 8.0 kb RNP-EGFP vectors. Of more than
a hundred clonal lines containing the hCMV-EGFP con-
struct the majority (60 of 112) showed no detectable
EGFP expression, with only a single clone displaying a
median expression level that exceeded 5000 fluorescence
units. In contrast, for clones generated with the 8.0 kb
RNP-EGFP construct, the great majority (74 of 86) did
show detectable EGFP expression and a large proportion
(63 of 86) had a median expression level exceeding 5000
units. 41 of 86 clones with the 8.0 kb RNP-EGFP construct
showed expression exceeding that of the best hCMV-EGFP
clone. Of the 12 clones generated with this construct that
showed no detectable EGFP expression, all those exam-
ined by Southern blot analysis proved to have deletions
extending (at least) into the RNP sequences (data not
The human HNRPA2B1/CBX3 (RNP) locus and constructs used in EGFP and EPO expression studies Figure 1
The human HNRPA2B1/CBX3 (RNP) locus and constructs used in EGFP and EPO expression studies. A. Organisation of the 
RNP genomic locus. The figure indicates the locations of the divergent promoters (arrows), the exons (black boxes) and the 8.0 
kb Hind III fragment that includes the 3 kb unmethylated CpG island. B. EGFP and EPO expression constructs. All constructs 
carried the Neor gene preceded by the SV40 promoter for selection of stable transfectants of CHO-K1 cells.
HindIII
3kb CpG island
HNRNPA2B1 CBX3
4.0kb RNP-EGFP
8.0kb RNP-EGFP
hCMV-EGFP EGFP SV40 NEOR hCMV
EGFP SV40 NEOR hCMV
EGFP SV40 NEOR hCMV
Esp3I Esp 3I
EGFP SV40 NEOR hCMV 1.5kb RNP-EGFP
B
A
8.0kb RNP-EPO
hCMV-EPO EPO SV40 NEOR hCMV
EPO SV40 NEOR hCMV
HindIIIBMC Biotechnology 2005, 5:17 http://www.biomedcentral.com/1472-6750/5/17
Page 4 of 9
(page number not for citation purposes)
shown). These deletions presumably occurred prior to or
during the integration process. Similar analysis of non-
expressing clones generated with the hCMV-EGFP con-
struct revealed many with no detectable deletion. These
results suggest that the 8.0 kb RNP fragment confers a sub-
stantial increase in the proportion of integration events
that lead to detectable gene expression.
Ideally, for large-scale manufacture of protein therapeu-
tics clonal cell lines producing the proteins are expanded
without drug selection from a master cell bank. Where
proteins are manufactured for use in humans the regula-
tory authorities require evidence that the manufacturing
process gives production that is stable (i.e that falls within
defined specification limits) over 25 to 30 generations of
culture. To investigate the suitability of vectors containing
the  RNP  CpG island fragments for this purpose, four
clonal lines generated with the 8.0 kb RNP-EGFP
construct and showing median expression that exceeded
5000 fluorescence units after 118 generations of culture in
the presence of G418, were cultured with and without
drug selection for a further 213 generations. For all four
clones no reduction was observed in the percentage of
cells showing expression exceeding 1000 fluorescence
units after 213 generations of culture with drug selection.
Also for all four clones no reduction was observed in the
percentage of such cells after 38 generations without drug
selection. Slight instability of expression was observed for
one clone, #54, on very prolonged culture without drug
selection. As shown in Figure 4B for this clone the percent-
age of cells showing expression exceeding 1000 units
declined from 95% to 79% between 38 and 213 genera-
tions, while for the other three clones, exemplified by #67,
no such decline was observed.
RNP CpG island vectors give improved yields of 
recombinant proteins in CHO cells
The utility of the RNP CpG island vectors for recombinant
protein production was further examined using the eryth-
ropoietin (EPO) gene. Constructs were generated with the
EPO cDNA sequence under the control of either the hCMV
promoter alone or in combination with the 8.0 kb RNP
fragment (Figure 1B). Following stable transfection into
CHO-K1 cells EPO production was measured for pools of
transfectants over 174 generations of culture (Figure 5A).
The 8.0 kb RNP-EPO construct gave a substantially higher
yield of EPO at all time points than that observed with
hCMV-EPO. On average the RNP CpG island vector gave a
twenty-fold improved yield of EPO, and the improved
production was maintained through at least 100 genera-
tions of subculture.
Clonal CHO-K1 lines were derived from transfectants gen-
erated with the hCMV-EPO and 8.0 kb RNP-EPO expres-
FACScan analysis of EGFP expressing CHO-K1 cells Figure 2
FACScan analysis of EGFP expressing CHO-K1 cells. Following stable transfection with hCMV-EGFP, 8.0 kb RNP-EGFP, or 4.0 kb 
RNP-EGFP, pools of >100 transfectants were cultured continuously with drug selection for 200 generations, and FACScan anal-
ysis conducted after 33 and 200 generations. The results are plotted as green fluorescence on a logarithmic scale (FL1-H) ver-
sus number of events on a linear scale (counts). Figures for gate M1 are % cells with undetectable fluorescence; those for gate 
M2 are % cells showing greater than 1000 fluorescence units.
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sion constructs. Twenty clones were chosen at random
and assessed for EPO production (Figure 5B). For clones
derived with hCMV-EPO, 6/20 produced no detectable
EPO and only 1/20 (C4) showed a yield (0.85 µg/ml)
exceeding 0.5 µg/ml. In marked contrast, 20/20 clones
harbouring 8.0 kb RNP-EPO showed detectable EPO pro-
duction, 18/20 produced more than 0.5 µg/ml, 16/20
produced more than 1 µg/ml, and one clone (R16) pro-
duced almost 14 µg/ml. Thus inclusion of the 8.0 kb RNP
fragment in the expression construct resulted in the facile
isolation of clones with improved EPO production, the
average yield for the twenty clones being twenty-one-fold
higher than with hCMV-EPO, and the best producing
clone with 8.0 kb RNP-EPO  giving sixteen-fold higher
productivity than C4, the highest producing hCMV-EPO
line.
Increased expression with RNP CpG island vectors is not 
due to increased transgene copy number
The possibility that CpG island vectors give improved
transgene expression through integration at increased
copy number was evaluated by conducting copy number
analysis on genomic DNA for clonal lines expressing
EGFP following transfection with hCMV-EGFP (13 lines)
RNP CpG island fragments enhance the level and stability of EGFP expression in stably transfected CHO-K1 cells Figure 3
RNP CpG island fragments enhance the level and stability of EGFP expression in stably transfected CHO-K1 cells. A. Histo-
grams representing the median fluorescence and percentage cells with detectable EGFP expression for CHO-K1 cells stably 
transfected with hCMV-EGFP, 8.0 kb RNP-EGFP or 4.0 kb RNP-EGFP. Following transfection pools of >100 transfectants were cul-
tured continuously with drug selection for 107 generations and FACScan analysis conducted every few days. B. Histograms 
representing the median fluorescence and percentage cells with detectable EGFP expression for CHO-K1 cells stably trans-
fected with hCMV-EGFP, 4.0 kb RNP-EGFP or 1.5 kb RNP-EGFP. Following transfection pools of >100 transfectants were cultured 
continuously with drug selection for 107 generations and FACScan analysis conducted every few days
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or 8.0 kb RNP-EGFP (9 lines). All these lines proved to
have copy numbers of two or three. The highest expressing
clones with both constructs had a copy number of three,
but so did some of the lowest expressing clones for both
constructs. Overall, statistical analysis of variance (by the
ANOVA single factor method) indicated no significant
correlation between level of expression and copy number
for either construct.
Conclusion
The hCMV promoter has been by far the most commonly
used promoter for high level transgene expression in
mammalian cells, for a wide range of applications that
includes the production of protein therapeutics in cul-
tured cells, transgenic animals and gene therapies. Its util-
ity in expressing transgenes for all these applications,
however, has been hindered by its susceptibility to silenc-
ing, largely through effects involving adverse chromatin
structure. For example, the isolation of clonal cell lines or
transgenic animals showing stable, high level expression
of transgenes is usually a slow and labour-intensive proce-
dure because most integration events lead to silencing.
The results we report here show that incorporating a RNP
CpG island fragment immediately upstream of the hCMV
promoter gives major benefits in expression from the
The 8.0 kb RNP CpG island fragment gives a high proportion of clonal CHO-K1 cell lines showing high-level, stable expression  of EGFP Figure 4
The 8.0 kb RNP CpG island fragment gives a high proportion of clonal CHO-K1 cell lines showing high-level, stable expression 
of EGFP. Following stable transfection of CHO-K1 cells clonal lines were derived by limiting dilution. Median fluorescence lev-
els were measured for each clone by FACScan analysis after 22 generations of culturing with drug selection. A. Histograms 
representing the median fluorescence levels for clones generated with hCMV-EGFP (n = 112) and 8.0 kb RNP-EGFP (n = 86). B. 
FACscan analysis of two clonal lines described in A. Clonal cell lines were subcultured continuously with or without drug selec-
tion for a further 213 generations, with analysis after 38 and 213 generations. Figures for gate M1 are % cells showing greater 
than 1000 fluorescence units.
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latter. These benefits include a substantial increase in the
median level of expression observed in pools of transfect-
ants, together with a substantial improvement in the pro-
portion of cells in the pool that express. The CpG island
fragments reproducibly gave 20 to 40-fold increases in the
level of expression observed. With both EGFP and EPO
these dramatically increased expression levels were main-
tained through at least 100 generations of subculture. The
CpG island fragments also enabled the rapid and facile
isolation of clonal cell lines showing stable, high level
expression of EGFP and EPO.
Our previous work [9] showed that a 16 kb DNA fragment
containing the RNP CpG island conferred resistance to
heterochromatin-mediated silencing of expression from
the endogenous RNP promoter and reduced position
effect variegation, giving very consistent expression levels
in tissue culture cells. In the studies we report here, con-
structs with the 8.0 kb RNP CpG island fragment
preceding the hCMV promoter gave detectable levels of
transgene expression for all integration events in which
the construct remained intact, together with substantial
increases in the level of expression from the hCMV
The 8.0 kb RNP fragment increases the yield of EPO in stably transfected CHO-K1 cells Figure 5
The 8.0 kb RNP fragment increases the yield of EPO in stably transfected CHO-K1 cells. A EPO production from pools of 
CHO-K1 cells stably transfected with hCMV-EPO or 8.0 kb RNP-EPO. Following selection on G418 pools of transfectants were 
cultured continuously with drug selection for 174 generations. Assays for EPO production were conducted every few days. B 
EPO production from clonal CHO-K1 cell lines derived with hCMV-EPO or 8.0 kb RNP-EPO. Clonal lines were derived by limit-
ing dilution from pools of transfectants selected on G418. Colonies were expanded for 35 generations with drug selection 
prior to assay for EPO production.
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promoter. Analysis of variance (by the single factor
ANOVA method) showed these increases to be statistically
significant (p = 8.13E-27). These constructs, however,
gave much greater variability in levels of expression than
those observed in our previous work with a larger CpG
island fragment and the endogenous RNP promoter. It is
not clear whether the greater variability in expression level
for the CpG island constructs in the studies we report here
than our previous ones is due to the use of a different pro-
moter or different cell line, or occurs because sequences
giving more complete isolation from the effects of chro-
matin structure or transcriptional activity adjacent to the
integration site are present on the 16 kb fragment but not
on the 8 kb fragment.
The present results demonstrate two very important appli-
cations of this novel transgene expression technology.
One is the rapid production of recombinant proteins, in
the quantities required for basic research, drug discovery
and preclinical studies, using stable pools of transfectants.
The CpG island technology circumvents the need for slow,
labour intensive screening of clonal lines for this purpose.
The other is faster and easier identification of clonal cell
lines that show stable, high level production as candidates
for large scale manufacture of protein therapeutics. With
the CpG island technology screening of only 20 clonal
CHO cell lines was sufficient to identify lines showing
very high yields of EPO, the latter being a blockbuster pro-
tein drug that is widely used to treat anaemia associated
with renal failure and chemotherapy. It is noteworthy that
the hCMV and CHO cells used in these experiments are
the promoter and cells most commonly used for commer-
cial manufacture of protein therapeutics.
Through their capacity to confer an increase in the propor-
tion of integration events that are productive, together
with improvements in the level of transgene expression,
RNP CpG island vectors have many other potential appli-
cations, including use in mammalian cell-based in vitro
screens for drug discovery, transgenic animals for basic
research and drug discovery, and gene therapy. For some
of these applications, notably those involving transgene
delivery with integrating viral vectors, gene expression ele-
ments of small size are required. The data we present here
suggest that the 1.5 kb RNP fragment confers major bene-
fits in expression level from the hCMV promoter. Efforts
to further characterise and minimise these elements are
ongoing, but the 1.5 kb fragment should be small enough
for incorporation into most viral vectors.
The mechanism by which the RNP CpG island reduces
silencing and improves transgene expression is under
investigation in our laboratories. The data we report here
show that the mechanism does not involve increasing the
copy number of the integrated transgene. Our results to
date, reported previously [9] and in this paper, are consist-
ent with these elements being able to establish and main-
tain a more open chromatin domain irrespective of the
local chromosome environment. We propose that the
promoter-containing CpG-islands of housekeeping genes
possess a chromatin remodelling function and that this is
designated a "Ubiquitously-acting Chromatin Opening
Element", or "UCOE".
Methods
Expression vectors
hCMV-EGFP was vector pEGFP-N1 (Clontech, Cambridge,
UK), which contains the hCMV promoter/enhancer on a
589 bp fragment. RNP  CpG island-containing vectors
were constructed by inserting genomic fragments from the
RNP locus into the blunted Ase I  site of hCMV-EGFP.
These fragments were blunted versions of the 8.0 kb Hind
III fragment, 4.0 kb BamH I-Hind III fragment and 1.5 kb
Esp3I fragments to give 8.0 kb RNP-EGFP, 4.0 kb RNP-
EGFP and 1.5 kb RNP-EGFP respectively (Figure 1B).
The erythropoietin (EPO) cDNA was isolated by PCR ampli-
fication from a Quick Clone Foetal Liver cDNA library
(Clontech, Cambridge, UK). The resulting 705 bp product
was subcloned using the TA-cloning vector pCR3.1 (Invit-
rogen, Paisley, UK) generating pCR-EPO. hCMV-EPO was
constructed by subcloning an NheI-NotI fragment from
pCR-EPO into the respective sites within the vector pEGFP-
NI. 8.0 kb RNP-EPO was constructed by subcloning the
blunt-ended 8.0 kb Hind III fragment into the blunted Ase
I site of hCMV-EPO (Figure 1B).
Cell lines and transfections
CHO-K1 cells were grown in HAMS F12 (Invitrogen, Pais-
ley, UK) plus 4500 mg/l L-ananyl-L-glutamine, 10 µg/ml
each of penicillin and streptomycin, and 10% (v/v) heat
inactivated foetal calf serum (FCS; Invitrogen, Paisley,
UK). Transfection was carried out by electroporation
using approximately 107 cells from 80% confluent cul-
tures and a BioRad Gene Pulser II ™ set to deliver a single
pulse of 975 µF at 250 V. Transfections used 1 µg of line-
arised hCMV plasmid and equivalent molar quantities for
expression vectors of different size. Stably transfected cells
were selected and maintained in growth medium contain-
ing 400 µg/ml geneticin sulphate (G418; Sigma, Poole,
UK). Clonal cell lines were derived from stable transfected
pools by standard limiting dilution techniques.
Quantification of transgene expression
Analysis of cells transfected with EGFP reporter constructs
was with a Becton-Dickinson FACScan using the parental
CHO-K1 cell line as a background, autofluorescence con-
trol. For EPO quantitation cells were seeded at 106 cells/
well in 6-well plates and incubated in FCS-containing
medium over 48 hours. Conditioned medium samplesPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Biotechnology 2005, 5:17 http://www.biomedcentral.com/1472-6750/5/17
Page 9 of 9
(page number not for citation purposes)
were assayed for EPO using a Quantikine IVD ELISA kit
(R&D Systems Europe, Abingdon, UK)
Transgene copy number analysis
Copy number was determined by quantitative PCR
(QPCR) using oligonucleotide primers and Beacon
probes designed using Beacon Designer v2.0 software
(Premier Biosoft International, CA, USA) specific to
hCMV or EGFP sequences and to the endogenous house-
keeping gene β -actin as a copy number control. Multiplex
QPCR reactions containing optimised oligonucleotide
and probe concentrations and ~500 ng of template DNA
were performed on the MX4000™ multiplex PCR quanti-
tative PCR system according to the manufacturers proto-
col (Stragene, La Jolla, CA), and subsequent data
manipulations performed using the MX4000™ analysis
software (Stratagene, La Jolla, CA). Copy number was
assigned by comparison of the hCMV and/or EGFP: β -
actin endpoint fluorescence ratio with that of a verified
single copy integrant.
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